Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q14562

UPID:
DHX8_HUMAN

ALTERNATIVE NAMES:
DEAH box protein 8; RNA helicase HRH1

ALTERNATIVE UPACC:
Q14562

BACKGROUND:
The ATP-dependent RNA helicase DHX8, known alternatively as DEAH box protein 8 and RNA helicase HRH1, is integral to the spliceosome's pre-mRNA splicing process. By facilitating the release of RNA from the spliceosome, it ensures the efficient export of spliced mRNA from the nucleus, underscoring its vital role in gene expression.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ATP-dependent RNA helicase DHX8 holds promise for identifying new therapeutic avenues. Given its critical involvement in RNA splicing and export, targeting DHX8 could lead to innovative treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.